Importantly, T-ALL patients with high NFE2L2 levels exhibited reduced overall survival, so one might speculate that drug resistance induced by increased GSH could be at least a contributing factor in these tumours. This evidence concerns the gene NFE2L2 and acute lymphoblastic leukemia.